Insider Selling: Establishment Labs Holdings Inc. (NASDAQ:ESTA) CEO Sells $174,008.66 in Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) CEO Quiros Juan Jose Chacon sold 3,866 shares of the company’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $45.01, for a total value of $174,008.66. Following the transaction, the chief executive officer now owns 215,030 shares of the company’s stock, valued at $9,678,500.30. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Thursday, July 11th, Quiros Juan Jose Chacon sold 3,641 shares of Establishment Labs stock. The stock was sold at an average price of $45.04, for a total value of $163,990.64.
• On Monday, July 1st, Quiros Juan Jose Chacon sold 6,839 shares of Establishment Labs stock. The stock was sold at an average price of $45.30, for a total value of $309,806.70.

Establishment Labs Trading Down 1.6 %

NASDAQ:ESTA opened at $44.89 on Friday. Establishment Labs Holdings Inc. has a 1 year low of $16.96 and a 1 year high of $73.00. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -14.30 and a beta of 1.24. The business has a fifty day moving average of $49.13 and a 200-day moving average of $44.69. The company has a debt-to-equity ratio of 3.38, a quick ratio of 2.73 and a current ratio of 4.24.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Wednesday, May 8th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.07. Establishment Labs had a negative return on equity of 206.05% and a negative net margin of 53.12%. The business had revenue of $37.17 million during the quarter, compared to analysts’ expectations of $35.61 million. During the same quarter last year, the business posted ($0.48) earnings per share. The company’s quarterly revenue was down 20.1% on a year-over-year basis. Equities analysts predict that Establishment Labs Holdings Inc. will post -1.79 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. FNY Investment Advisers LLC bought a new position in Establishment Labs during the fourth quarter valued at about $93,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Establishment Labs by 67.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,591 shares of the company’s stock valued at $119,000 after buying an additional 1,845 shares in the last quarter. SG Americas Securities LLC bought a new position in Establishment Labs during the fourth quarter valued at about $120,000. Legato Capital Management LLC boosted its stake in Establishment Labs by 63.1% during the fourth quarter. Legato Capital Management LLC now owns 8,438 shares of the company’s stock valued at $218,000 after buying an additional 3,263 shares in the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in Establishment Labs during the first quarter valued at about $263,000. Institutional investors own 72.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ESTA. Mizuho upped their price objective on Establishment Labs from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, June 6th. Citigroup decreased their price target on Establishment Labs from $60.00 to $50.00 and set a “neutral” rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Establishment Labs currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.00.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.